Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia.
about
The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experiencePneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.Effectiveness of 7-valent pneumococcal conjugate vaccine against radiologically diagnosed pneumonia in indigenous infants in AustraliaDevelopment of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa.A high burden of respiratory syncytial virus associated pneumonia in children less than two years of age in a South East Asian refugee population.High rates of pneumonia in children under two years of age in a South East Asian refugee population.Biomarkers of Host Response Predict Primary End-Point Radiological Pneumonia in Tanzanian Children with Clinical Pneumonia: A Prospective Cohort StudyPneumonia research to reduce childhood mortality in the developing world.Active hospital-based surveillance of invasive pneumococcal disease and clinical pneumonia in infants and young children in two Polish countiesHigher risk for incident heart failure and cardiovascular mortality among community-dwelling octogenarians without pneumococcal vaccination.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia.Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries.Community-acquired pneumonia in children - a changing spectrum of disease.Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.Changing patterns of rotavirus genotypes in Turkey.The radiological diagnosis of pneumonia in children
P2860
Q28088507-8B4681DE-4DC5-4031-B0D4-A6A4DBD7C379Q30235055-CC049BB2-EB8B-4D61-980E-5E6B42602B99Q33623151-1C107CFC-852B-4A2F-A539-BE8DD0378092Q34124926-54D25F0B-A741-42A6-974C-1B9867925E0CQ34491031-27501F84-EA7C-43E2-B34A-FCC99B03B8E5Q34548409-305CCE19-F2EB-4E54-9860-92EF7BBCB06DQ35772162-C6DE3DA9-1FAC-416A-8C4E-BF371C08B047Q36513346-A7278F82-74E4-4FAA-9002-4B886DB6E3D1Q36958318-8800A2EF-7B7E-4CB6-82C1-37F2F05CE851Q37248663-9BC14CF6-7A0B-4D15-8519-3CCFB8B6F8A4Q37621054-A21E86F0-1DF6-4735-AC88-2EB51885FCC8Q38177359-5BBACA92-C71F-4816-98E9-9BEF110DA177Q42362274-AEABA0F5-F804-4ACC-BC08-22B4A6AF84C8Q43697135-A4F56774-C00B-4C9F-B80B-87E8E1242991Q54347540-F7712DAD-FDFA-4F22-87B7-91C474DE13D5Q59117031-C1189CEC-3580-46A2-8161-8ADF415F90B2
P2860
Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@en
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@nl
type
label
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@en
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@nl
prefLabel
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@en
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@nl
P50
P1476
Usefulness of C-reactive prote ...... n the prevention of pneumonia.
@en
P2093
Mariane Kohler
P356
10.1097/01.INF.0000195787.99199.4A
P577
2006-01-01T00:00:00Z